Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
ALL
What is your first choice TKI for pediatric patients with Ph+ ALL who are not on a study?
Answer from: at Academic Institution
The first choice for TKI in children/adolescents with Ph+ ALL should be dasatinib based on a recent study published in JAMA Oncology (Shen et al).
Sign In
or
Register
to read more
7488
Related Questions
What is your standard for monitoring triglyceride level during therapy for ALL, particularly in regards to receiving pegaspargase?
How can the integration of MRD assessments into treatment protocols be optimized to improve risk stratification and therapy decisions in T-ALL?
How do you choose between the different available CAR-T cell therapy products for the treatment of relapsed Ph-negative ALL?
What are your top takeaways in Hematologic Malignancies from ASH 2025?
Do you use G-CSF for a patient with ALL admitted for febrile neutropenia with prolonged count recovery?
When following current COG ALL protocols with the addition of two courses of blinatumomab to treatment for SR and HR patients, how frequently should surveillance bone marrow and MRD evaluations be performed?
What is your approach to chronic non-immune mediated thrombocytopenia management in children?
For pediatric patients with iron overload (high ferritin and transferrin saturation), do you perform HFE screening first, or proceed to non-HFE gene sequencing upfront to evaluate for HJV mutation as well?
How do you approach revaccination after chemotherapy, and what labs (if any) do you use to assess immune reconstitution?
How do you address non-adherence to medical treatment in adolescent and young adult oncology patients due to mental illness such as depression?